RET and non-small cell lung carcinoma: According to 2023 ESMO recommendations, all advanced non-squamous NSCLC cases should be tested for ALK, ROS1, NTRK, RET fusions, MET exon14 skipping mutations, BRAF, KRAS G12C and HER2 mutations in addition to EGFR mutations.